Category - Developments

Developments

Avivagen posts positive swine trial results in China

Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing. The trial evaluated OxC...

March 22, 2016

Developments

Can-Fite submits Phase 3 RA trial protocol to EMA

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted to the European Medicines Agency (EMA) a protocol design for a Phase 3 trial and registration plan for its lead compound, CF101, in the treatment of rheumatoid...

March 17, 2016

Developments

Venaxis ends transactions with Strand Life Sciences

Venaxis (NASDAQ:APPY), closely-held Strand Life Sciences of India and its U.S. subsidiary, Strand Genomics, have terminated a series of transactions between the companies. The termination affects an asset purchase...

March 15, 2016

Developments

TearLab Q4 revenue climbs 28%

Fourth quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) was $6.8-million, up 28% from $5.3-million a year ago. For all of 2015, revenue rose 28% to $25.2-million from $19.7-million for 2014. A net total of 258 TearLab...

March 8, 2016

Developments

Titan Pharma receives FDA feedback on Parkinson’s implant

The FDA has provided written feedback to Titan Pharmaceuticals (NASDAQ:TTNP) on the initial development plan for its proprietary ropinirole hydrochloride implant for Parkinson’s disease. Based on the FDA’s feedback on...

March 7, 2016

Developments

Pivotal Therapeutics unable to repay notes

Pivotal Therapeutics (CSE:PVO; OTC PINK:PVTTF) currently is unable to repay $7.7-million of convertible notes, which came due March 4, 2016, and at least one noteholder has advised the company that it intends to...

March 6, 2016

Developments

Titan’s Probuphine continues to build media attention

WMUR Channel 9 in Manchester, NH has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction...

February 26, 2016

Developments

Soricimed posts positive SOR-C13 data in solid tumors

Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers. The...

February 23, 2016

Developments

NovellusDx expands board, raises $10-million

Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board. “The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong...

February 19, 2016

Developments

FDA extends Probuphine action date

The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic...

February 19, 2016

Category - Developments

Avivagen posts positive swine trial results in China

Can-Fite submits Phase 3 RA trial protocol to EMA

Venaxis ends transactions with Strand Life Sciences

TearLab Q4 revenue climbs 28%

Titan Pharma receives FDA feedback on Parkinson’s implant

Pivotal Therapeutics unable to repay notes

Titan’s Probuphine continues to build media attention

Soricimed posts positive SOR-C13 data in solid tumors

NovellusDx expands board, raises $10-million

FDA extends Probuphine action date

General

More